APTO logo

Aptose Biosciences, Inc.


APTO: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.


Show APTO Financials

Consumer Interest
SEC Filings

Recent trades of APTO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by APTO's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof Mar. 22, 2022
  • Patent Title: Aryl imidazoles for treatment of cancer Oct. 19, 2021
  • Patent Title: Compositions and methods for treating cancers Aug. 31, 2021
  • Patent Title: Aryl imidazoles and their use as anti-cancer agents Sep. 25, 2018
  • Patent Title: Compositions and methods for treating cancers Feb. 14, 2017
  • Patent Title: 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Mar. 24, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of APTO in WallStreetBets Daily Discussion


Recent insights relating to APTO

CNBC Recommendations

Recent picks made for APTO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in APTO

Corporate Flights

Flights by private jets registered to APTO